- Core biopsy devices
- Core biopsy needles
- Core biopsy guns
- Needle-based biopsy devices
- Vacuum-assisted biopsy devices
- Aspiration biopsy needles
Biopsy Devices Market size was valued at USD 2.64 billion in 2022 and is poised to grow at a CAGR of 8.5% from 2023-29. The biopsy is a surgical operation that involves removing tissue from an organ to detect the existence or degree of a disease, most commonly cancer and inflammatory disorders. Surgeons, radiologists, and interventional cardiologists are the most common practitioners. As a confirmatory test for cancer and celiac disease, biopsies can be conducted on any organ using specialised biopsy instruments. The type of organ under consideration determines how each biopsy equipment is used. Advanced imaging technologies, such as MRI-guided biopsy, stereotactic-guided biopsy, ultrasound-guided biopsy, CT scan, and others, can be used in conjunction with traditional biopsy techniques to perform biopsy with accuracy and least invasiveness. Biopsies of body organs such as the lungs, liver, and kidneys are performed using these integrated methods. The biopsy is a minimally invasive surgical process performed to remove the tissue from the body for the determination of presence or extent of diseases such as cancer and inflammatory conditions. Generally, the biopsy is carried by radiologists, surgeons, and interventional cardiologists to confirm the presence of disease. A biopsy can be carried for the majority of organs in the body with the aid of specific biopsy devices. The various types of biopsy devices include skin biopsy, shave biopsy, fine needle aspiration, excision and incision biopsy, and vacuum-assisted biopsy among others. Conventional biopsy devices are complimented with the advanced imaging technologies like stereotactic-guided biopsy, CT scan, MRI-guided, ultrasound-guided biopsy, and others. These devices are helping to perform the biopsies in critical areas such as liver, kidney, and lungs.
Fastest Growing Market
Biopsy devices market is growing at a significant CAGR due to increase in the prevalence of cancer around the globe. Technological advancements of biopsy devices and increase in the demand for biopsy devices in disease screening for early treatment propel the biopsy devices market. Acquisitions and mergers, collaborations, product and patent approvals, and product launches are key strategies followed by the players for increasing market revenue growth. For instance, in September 2014, Argon Medical Devices, Inc. acquired Promex Technologies, LLC for diversification of business segment into the soft-tissue biopsy devices. Similarly, in September 2015, MDxHealth acquired the NovioGendix for developing its product portfolio in the prostate cancer diagnosis. Furthermore, in January 2015, Intact Medical Corp. has received the FDA approval for its minimally invasive breast biopsy devices.
The biopsy devices market size was valued at USD 2.64 billion in 2022
Argon Medical Devices (U.S.) Cardinal Health, Inc. (U.S.) Boston Scientific Corporation (U.S.) Medtronic plc (Ireland) B. Braun Melsungen AG (Germany) Olympus Corporation (Japan)
Asia Pacific is the fastest-growing biopsy devices market